The Next Steps for Personalized Health Care: Incentivizing Product Development
This article was originally published in RPM Report
Executive Summary
Roche has positioned itself as a leader in the development of more "personalized" health care products. What's needed now, CEO Abercrombie says, is a commitment from FDA to develop consistent approval standards and from CMS to guarantee coverage.
You may also be interested in...
The Rush to Comparative Effectiveness: FDA's Woodcock Hopes It Won't Overshadow Personalized Medicine
Comparative effectiveness research is a central theme of the Obama Administration's health reform effort. But as the debate heats up on Capitol Hill, one top FDA official, Janet Woodcock, doesn't want to lose sight of an increasingly important drug development strategy: personalized medicine.
The Rush to Comparative Effectiveness: FDA's Woodcock Hopes It Won't Overshadow Personalized Medicine
Comparative effectiveness research is a central theme of the Obama Administration's health reform effort. But as the debate heats up on Capitol Hill, one top FDA official, Janet Woodcock, doesn't want to lose sight of an increasingly important drug development strategy: personalized medicine.
An Activist FDA Could Benefit Drug Development
Former FDA Commissioner David Kessler sees a big opportunity for FDA to clarify approval criteria for cancer drugs and personalized medicine projects in the period after the upcoming election. This is time to begin planning for that period of opportunity.